Galecto reaps $64M to bring lead drug across IPF finish line, while making moves in NASH and beyond

Back in 2018, Hans Schambye raised $90 million to kick off a late-stage trial that could put Galecto Biotech’s lead drug on the final …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Galec­to reaps $64M to bring lead drug across IPF fin­ish line, while mak­ing moves in NASH and be­yond